Quantcast

Industry news that matters to you.  Learn more

Archives for October 2015

Cytox Announces Participation in INSIGHT Alzheimer’s Study

Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has confirmed its participation in the pioneering French INSIGHT study of Alzheimer’s disease (AD). The Cytox proposal, ‘Single Nucleotide Polymorphism (SNP) Profiling as an Approach to Risk Stratification for Future Cognitive Decline in Elderly Subjective Memory Complainers’, has been reviewed and approved by the INSIGHT Scientific Committee.

Researchers Close in on a Blood Test for Alzheimer’s Disease, Giving Physicians Hope for Slowing Symptoms Through Preclinical Detection

Researchers from the Rowan University School of Osteopathic Medicine are nearing development of a blood test that can accurately detect the presence of Alzheimer’s disease, which would give physicians an opportunity to intervene at the earliest, most treatable stage.

Luminex Corporation Receives CE-IVD Mark for NxTAG Respiratory Pathogen Panel

Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for its NxTAG® Respiratory Pathogen Panel. The Panel detects 21 clinically-relevant viral and bacterial respiratory pathogens, including the atypical bacteria Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila. The NxTAG Respiratory Pathogen Panel is the only respiratory assay that easily enables laboratories to simultaneously detect 21 respiratory pathogens in a single closed tube system that scales to accommodate changes in throughput needed to respond to seasonal changes in demand, such as during flu season.

BioClinica Launches New eClinical CRO Partner Alliance Program to Maximize CROs’ Business and Scientific Goals

BioClinica®, Inc., a specialty clinical trials technology services provider, today announced the roll out of a new eClinical CRO Partner Alliance program, accelerating adoption of industry-leading eHealth solutions by CROs. The decision to redesign the CRO partner channel comes in response to growing demand for a premier eClinical technology platform that enables CROs and sponsors to conduct studies in an efficient and accelerated manner.

Ariosa Diagnostics’ Harmony Prenatal Test Now Performed in Australia and United Kingdom at Sonic Healthcare Laboratories

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ariosa Diagnostics, Inc., a global leader in non-invasive prenatal testing (NIPT) technology and maker of the Harmony™ Prenatal Test, in conjunction with Australian company Sonic Healthcare, today announced that Sonic Healthcare has been granted a license to perform the Harmony Prenatal Test in its Australian and United Kingdom labs. Under the license, Sonic Healthcare will provide the Harmony Prenatal Test and cell-free DNA System, developed at Ariosa’s California laboratory, through Sonic Genetics in Australia and Sonic’s UK counterpart, The Doctors Laboratory (TDL).